Merck (MRK) Non Operating Interest Expenses (2011 - 2013)

Merck (MRK) has reported Non Operating Interest Expenses for 3 consecutive years, with $184.0 million the latest figure, recorded in Q1 2013.

• On a quarterly basis, Non Operating Interest Expenses rose 5.14% year-over-year to $184.0 million in Q1 2013; TTM through Mar 2013 was $724.0 million, a 4.32% increase from a year earlier, with the FY2012 full-year figure at $714.0 million, up 2.73% from the prior year.
• Non Operating Interest Expenses was $184.0 million for Q1 2013 at Merck, down from $190.0 million in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $190.0 million in Q4 2012 and troughed at $170.0 million in Q2 2011.
• A 3-year average of $178.2 million and a median of $176.0 million in 2011 frame the typical range for Non Operating Interest Expenses.
• The widest YoY moves for Non Operating Interest Expenses: up 9.83% in 2012, down 5.91% in 2012.
• Over 3 years, Non Operating Interest Expenses stood at $173.0 million in 2011, then advanced by 9.83% to $190.0 million in 2012, then slipped by 3.16% to $184.0 million in 2013.
• The last three Non Operating Interest Expenses figures came in at $184.0 million (Q1 2013), $190.0 million (Q4 2012), and $178.0 million (Q3 2012), per Business Quant data.